Hims & Hers Health CEO Andrew Dudum has called Anthropic's latest AI breakthrough 'transformative' for population health, signaling a shift from 'super helpful' to 'superhuman' capabilities. The comments come as Hims expands its healthcare ecosystem and faces growing competition from WeightWatchers and Eli Lilly.
TL;DR
- Hims CEO Andrew Dudum praises Anthropic's AI advancements, highlighting their potential impact on healthcare.
- Hims is expanding its healthcare super app, adding partners across various health categories and launching Labs AI.
- Competition in the healthcare space is intensifying, with WeightWatchers and Eli Lilly also making significant moves.
What happened
Hims & Hers Health CEO Andrew Dudum described Anthropic's latest AI breakthrough as 'transformative' for population health, noting the shift from 'super helpful' to 'superhuman' capabilities. This follows Anthropic's claim that its Claude models are accelerating AI development, potentially leading to recursive self-improvement.
Hims is building a comprehensive healthcare super app, recently adding partners like iFIT, HelloFresh, and Dexcom's Stelo continuous glucose monitor. The company also launched Labs AI, an AI healthcare assistant designed to help users understand lab results and health risks.
Despite these advancements, Hims' stock slipped 1% in overnight trading, reflecting investor concerns about rising competition. WeightWatchers announced that its Med+ program is now available through Eli Lilly's LillyDirect platform, offering patients access to GLP-1 medications and support services.
Why it matters
For developers and startups, the integration of advanced AI models like Anthropic's Claude into healthcare platforms presents new opportunities for innovation. The potential for AI to accelerate its own development could lead to breakthroughs in various fields, including healthcare.
Investors should watch how Hims navigates the competitive landscape. The company's expansion into a healthcare super app and its strategic partnerships could position it as a key player, but the intensifying competition from WeightWatchers and Eli Lilly adds uncertainty.
Key facts
- Hims CEO Andrew Dudum called Anthropic's AI breakthrough 'transformative' for population health.
- Anthropic claims its Claude models are accelerating AI development, with engineers shipping 8x more code per quarter compared to 2021-2025.
- Hims added partners like iFIT, HelloFresh, and Dexcom's Stelo to its Hims & Hers Benefits platform.
- Labs AI, launched by Hims, is designed to help users understand lab results and health risks.
- Hims' stock slipped 1% in overnight trading, reflecting investor concerns about competition.
- WeightWatchers' Med+ program is now available through Eli Lilly's LillyDirect platform.
- Hims has expanded into diagnostics, hormone health, preventive care, lab testing, and weight management.
- Hims stock has declined 48% over the past year.
Context
The healthcare industry is increasingly turning to AI to improve patient outcomes and streamline care. Companies like Hims are leveraging AI to build comprehensive healthcare platforms, integrating various health services into a single ecosystem.
Anthropic's advancements in AI, particularly the potential for recursive self-improvement, could have far-reaching implications. As AI systems become more capable, they could drive innovation in healthcare, science, and other fields.
The competition in the healthcare space is heating up, with companies like WeightWatchers and Eli Lilly making significant moves. This intensifying competition could lead to better services for consumers but also poses challenges for companies like Hims.
